0 128

Cited 0 times in

Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration

Authors
 Hae Min Kang  ;  Sung Jun Lee  ;  Chul Gu Kim  ;  Eun Jee Chung  ;  Hyoung Jun Koh 
Citation
 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, Vol.254(9) : 1681-1692, 2016 
Journal Title
 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 
ISSN
 0721-832X 
Issue Date
2016
MeSH
Aged ; Angiogenesis Inhibitors/administration & dosage ; Female ; Fluorescein Angiography ; Fluorocarbons/administration & dosage* ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Macula Lutea/diagnostic imaging* ; Male ; Prospective Studies ; Ranibizumab/administration & dosage* ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity ; Wet Macular Degeneration/diagnosis ; Wet Macular Degeneration/therapy*
Keywords
Age-related macular degeneration ; Perfluoropropane ; Posterior vitreous detachment ; Vitreomacular adhesion ; Vitreomacular traction
Abstract
PURPOSE: To evaluate the efficiency of gas-assisted vitreomacular adhesion (VMA) release combined with intravitreal ranibizumab injections for exudative age-related macular degeneration (AMD) patients. MATERIALS AND METHODS: This prospective, interventional case series included a total of 23 eyes of 22 patients. The eyes were treated with intravitreal injection of 0.3 mL of perfluoropropane (C3F8) gas and concomitant intravitreal ranibizumab injection to stimulate VMA release. After three initial loading injections, additional intravitreal ranibizumab injections were performed pro re nata. Over a 12-month period, monthly examinations were performed for best-corrected visual acuity (BCVA, logMAR; logarithm of the minimum angle resolution), optical coherence tomography, and dilated fundus examinations. RESULTS: After gas injection, 22 eyes (95.7 %) showed complete VMA release at 1 week. Complete VMA was achieved in all eyes at 2 months after VMA release, without serious ocular adverse events except one patient who developed a retinal tear. Mean BCVA was 0.61?±?0.37 logMAR (20/81 Snellen equivalents) at baseline and 0.46?±?0.30 logMAR (20/57 Snellen equivalents) at 12 months (P?=?0.135). Mean central macular thickness was 357.9?±?128.6 μm at baseline and 245.6?±?60.0 μm at 12 months (P?=?0.188). Mean numbers of intravitreal ranibizumab injections were 4.8?±?2.4 times during 12 months (4 to 8 injections). CONCLUSION: Gas-assisted VMA release can be used as an efficient alternative for exudative AMD patients with obvious VMA.
Full Text
https://link.springer.com/article/10.1007%2Fs00417-015-3257-y
DOI
10.1007/s00417-015-3257-y
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152136
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse